Terns Pharmaceuticals, Inc. Income Statement

Income Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 1.00M
Gross Profit 1.00M
Operating items
Research & Development 28.03M31.31M39.62M63.50M70.11M
Selling, General & Administrative 9.00M19.55M22.41M39.06M31.76M
Operating Expenses 37.02M50.86M62.03M102.56M101.87M
Operating Income -37.02M-49.86M-62.03M-102.56M-101.87M
EBIT -37.02M-49.86M-62.03M-102.56M-101.87M
Non-operating items
Interest & Investment Income 0.06M0.17M2.11M12.90M13.29M
Other Non Operating Income 10.70M0.04M-0.07M-0.31M-0.01M
Non Operating Income -2.73M0.21M2.04M12.59M13.28M
Net income details
EBT -40.94M-49.73M-60.23M-90.02M-89.01M
Tax Provisions 0.81M0.51M0.36M0.26M0.55M
Profit After Tax -40.57M-50.16M-60.34M-90.21M-88.85M
Income from Non-Controlling Interests -0.52M
Income from Continuing Operations -41.75M-50.24M-60.58M-90.28M-89.56M
Consolidated Net Income -41.75M-50.24M-60.58M-90.28M-89.56M
Income towards Parent Company -41.75M-50.24M-60.58M-90.28M-89.56M
Net Income towards Common Stockholders -29.35M-50.16M-60.58M-90.28M-89.56M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 25.13M25.27M37.61M61.79M84.94M
Shares Outstanding (Diluted Average) 22.71M36.03M
EBITDA -37.02M-49.86M-62.03M-102.56M-101.87M
Shares Outstanding 0.34M25.27M53.72M